Valneva (VALN) has released an update.
Valneva SE, in collaboration with Pfizer, has announced the publication of Phase 2 clinical trial results for its Lyme disease vaccine candidate, VLA15, in The Lancet Infectious Diseases journal, showing promising immunogenicity and safety profiles. The vaccine targets the most prevalent Borrelia species in North America and Europe and could meet the increasing medical need for a Lyme disease vaccine, with no current approved vaccines. Phase 3 trials are ongoing, with a potential regulatory submission planned for 2026 if the trials are successful.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
